<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618367</url>
  </required_header>
  <id_info>
    <org_study_id>GYEYJR-1</org_study_id>
    <nct_id>NCT04618367</nct_id>
  </id_info>
  <brief_title>HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT</brief_title>
  <official_title>HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to evaluate the efficacy and safety of hepatic arterial infusion&#xD;
      chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and Sintilimab for&#xD;
      patients hepatocellular carcinoma and portal vein tumor thrombus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin&#xD;
      was effective and safe for hepatocellular carcinoma. Lenvatinib was non-inferior to sorafenib&#xD;
      in overall survival in untreated advanced hepatocellular carcinoma, and Sintilimab, an&#xD;
      programmed cell death protein-1 (PD-1) antibody, was effective and tolerable in patients with&#xD;
      hepatocellular carcinoma and portal vein tumor thrombus. No study has evaluated HAIC plus&#xD;
      Lenvatinib and Sintilimab. Thus, the investigators carried out this prospective, single-arm&#xD;
      study to find out it.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival rate at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Progression was defined as progressive disease by independent radiologic review according to mRECIST or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>6 months</time_frame>
    <description>OS is the length of time from the date of randomization until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>PFS is defined as the time from the date of randomization to the date of the first objectively documented tumor progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>6 months</time_frame>
    <description>ORR, as determined based on tumor response according to RECIST 1.1, is defined as the proportion of all randomized subjects whose best overall response (BOR) is either a CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Safety will be evaluated according to the NCI CTCAE Version 4.03. All observations pertinent to the safety of the study medication will be recorded on the CRF and included in the final report.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Liver Neoplasms</condition>
  <condition>Sintilimab</condition>
  <condition>Portal Vein Tumor Thrombus</condition>
  <arm_group>
    <arm_group_label>HAIC plus Lenvatinib and Sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 6 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 200 mg intravenously every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hepatic arterial infusion chemotherapy</intervention_name>
    <description>administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks</description>
    <arm_group_label>HAIC plus Lenvatinib and Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>12 mg (or 8 mg) once daily (QD) oral dosing.</description>
    <arm_group_label>HAIC plus Lenvatinib and Sintilimab</arm_group_label>
    <other_name>TKI inhibits</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>200mg intravenously every 3 weeks</description>
    <arm_group_label>HAIC plus Lenvatinib and Sintilimab</arm_group_label>
    <other_name>programmed cell death protein-1 (PD-1) antibody</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. clinical diagnosis of HCC; 2. age between18 and 75 years; 3. refused to sorafenib&#xD;
             treatment; 4. type I PVTT, type II PVTT, or type III PVTT. 5. Child-Pugh class A or B;&#xD;
             6. Eastern Cooperative Group performance status (ECOG) score of 0-2; 7. Hemoglobin ≥&#xD;
             8.5 g/dL Total bilirubin ≤ 30mmol/L Serum albumin ≥ 32 g/L ASL and AST ≤ 5 x upper&#xD;
             limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT&#xD;
             within normal limits Absolute neutrophil count (ANC) &gt;1,500/mm3 8. Prothrombin time&#xD;
             ≤18s or international normalized ratio &lt; 1.7. 9. Ability to understand the protocol&#xD;
             and to agree to and sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Diffuse HCC; 2. Extrahepatic metastasis; 3. Obstructive PVTT involving both the&#xD;
             left and right portal vein or main portal vein.&#xD;
&#xD;
             4. Serious medical comorbidities. 5. Evidence of hepatic decompensation including&#xD;
             ascites, gastrointestinal bleeding or hepatic encephalopathy 6. Known history of HIV&#xD;
             7. History of organ allograft 8. Known or suspected allergy to the investigational&#xD;
             agents or any agent given in association with this trial.&#xD;
&#xD;
             9. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy 10. Evidence of&#xD;
             bleeding diathesis. 11. Patients with clinically significant gastrointestinal bleeding&#xD;
             within 30 days prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kangshun Zhu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Second Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qunfnag Zhou, MD</last_name>
    <phone>86 19868000115</phone>
    <email>zhouqun988509@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qunfang Zhou, MD</last_name>
      <phone>86 19868000115</phone>
      <email>zhouqun988509@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 31, 2020</study_first_submitted>
  <study_first_submitted_qc>October 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>December 20, 2020</last_update_submitted>
  <last_update_submitted_qc>December 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhou Qunfang</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Carcinoma, Hepatocellular</keyword>
  <keyword>lenvatinib</keyword>
  <keyword>Sintilimab</keyword>
  <keyword>portal vein tumor thrombus</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>5-fluorouracil</keyword>
  <keyword>leucovorin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

